NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Authors
Keywords
NK-92, Cellular immunotherapy, CAR, Clinical trial, NK cell line, Tumor targeting
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 65, Issue 4, Pages 485-492
Publisher
Springer Nature
Online
2015-11-11
DOI
10.1007/s00262-015-1761-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
- (2015) Kurt Schönfeld et al. MOLECULAR THERAPY
- Influence ofex vivopurging with CliniMACS CD34+selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma
- (2013) Seung-Ah Yahng et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Cellular therapy of cancer with natural killer cells—where do we stand?
- (2013) Hans G. Klingemann CYTOTHERAPY
- Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells
- (2013) P. J. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetically Modified T Cells for the Treatment of Malignant Disease
- (2013) Agnieszka Wieczorek et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Bringing natural killer cells to the clinic: ex vivo manipulation
- (2013) R. W. Childs et al. Hematology-American Society of Hematology Education Program
- Therapeutic applications: natural killer cells in the clinic
- (2013) J. S. Miller Hematology-American Society of Hematology Education Program
- Signatures of Human NK Cell Development and Terminal Differentiation
- (2013) Merlin Luetke-Eversloh et al. Frontiers in Immunology
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
- (2012) Christiane Sahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma
- (2012) Silke Heidenreich et al. Clinical & Developmental Immunology
- Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging
- (2012) Christiane L. Mallett et al. CYTOTHERAPY
- Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model
- (2012) B. E. Swift et al. HAEMATOLOGICA
- Successful “in-flight” activation of natural killer cells during long-distance shipping
- (2012) Scott A. Koepsell et al. TRANSFUSION
- Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens
- (2011) Laurent Boissel et al. LEUKEMIA & LYMPHOMA
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shipping of therapeutic somatic cell products
- (2010) Theresa L. Whiteside et al. CYTOTHERAPY
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
- (2009) Laurent Boissel et al. LEUKEMIA RESEARCH
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors
- (2008) Reinhard Meier et al. NUCLEAR MEDICINE AND BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More